昭衍新药公告，拟将2025年度与生仝智能科技（北京）有限公司及其子公司的关联交易金额上限由500万元调整为2100万元，用于实验室系统 软件开发 及数据管理优化服务。交易定价基于成本加成方式，利润比例为10%-20%，并参考市场水平协商确定。公司称此举有助于提升信息化和智能化水平，符合公司整体利益，不会损害股东权益。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.